Related Experiment Video
Updated: Feb 16, 2026

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research
Published on: January 22, 2011
The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology
Daniel N Cagney1, Joohee Sul2, Raymond Y Huang3
1Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts.
Abstract:
In early 2016, the FDA and the National Institutes of Health (NIH) published the first version of the glossary included in the Biomarkers, EndpointS, and other Tools (BEST) resource.1 The BEST glossary was constructed to harmonize and clarify terms used in translational science and medical product development and to provide a common language used for communication by those agencies. It is considered a "living" document that will be updated in the future. This review will discuss the main biomarker and clinical outcome categories contained in the BEST glossary as they apply to neuro-oncology, as well as the overlapping and hierarchical relationships among them.
Related Concept Videos
Short-distance Transport of Resources
Precipitation Titration: Endpoint Detection Methods
In the Volhard method, a standard excess of AgNO3 is first added to the...
FDA Approved Drugs: Changes to Approved Drugs
Xylem and Transpiration-driven Transport of Resources
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Overview of Microsoft Excel as a Data Analysis Tool

